- French vaccine maker Valneva on Thursday reported a smaller half-year loss, as a rebound in global tourism boosted sales of its travel vaccines Ixiario and Dukoral. The group's net loss - French vaccine maker Valneva on Thursday reported a smaller half-year loss, as a rebound in global tourism boosted sales of its travel vaccines Ixiario and Dukoral.
"We delivered another strong quarter of growth, leading our first half vaccine sales to more than double year-over-year, while continuing to progress our clinical studies," Chief Financial Officer Peter Bühler said in a statement. The drugmaker is betting on its vaccine candidates for tick-borne Lyme disease and mosquito-borne Chikungunya, as it seeks to bounce back from its COVID-19 vaccine disappointment.